Review of recent literature pertaining to frequency, associations, mechanisms, and overall significance of sleep-wake disturbances (SWD) in the premotor and early phase of Parkinson's disease.
INTRODUCTION
Sleep-wake disturbances (SWD) are frequent in Parkinson's disease and are typically attributed to Parkinson's disease medications, poor sleep hygiene, and other nonmotor symptoms (NMS) such as nocturnal akinesia, pain, cramping, and nycturia. Over the past decade, notable advances have been made in the understanding of the role of the dopaminergic system in circadian mechanisms and sleep-wake physiology [1] . In addition, nondopaminergic systems are involved early in the pathogenesis of SWD in Parkinson's disease [2, 3] . These findings suggest that SWD are no longer solely a complication of advanced PD but can emerge, among other NMS, in the premotor stages as a primary manifestation of neurodegeneration [4] and increase in frequency with Parkinson's disease progression (Fig. 1) . Considering the importance of early diagnosis and intervention, the possibility that SWD may have prognostic value for the development of Parkinson's disease is intriguing.
This review will discuss first the most recent literature on SWD in the context of premotor and early stage of Parkinson's disease and then important recent evidence on the pathophysiology of SWD in early Parkinson's disease.
SUBJECTIVE SLEEP DISTURBANCES/ INSOMNIA
Two thirds of patients with Parkinson's disease report poor sleep quality [5] , many of them very early in the course of the disease [6, 7] . Recent studies confirm the high prevalence of subjective sleep disturbances in the early stages of Parkinson's disease and highlight their association with low quality of life [8, 9 && ,10
Parkinson's disease, suggesting that either the disease progression or the introduction of dopaminergic medication may negatively impact sleep quality. In the same study, patients with tremor dominant Parkinson's disease showed a better sleep profile than other nontremor-dominant phenotypes [9 && ]. In agreement with the reported subjective sleep disturbances, previous polysomnographic studies showed that patients with Parkinson's disease exhibit significant abnormalities in sleep architecture not only in fully developed motor Parkinson's disease [12] but in the early phase of the disease as well. These abnormalities include increased sleep latency, reduced sleep efficiency, reduced rapid eye movement (REM) sleep [7] , and significant changes in the REM and non-REM sleep architecture [13] [14] [15] [16] .
Recently In individuals at high risk of developing Parkinson's disease, RBD symptoms (mainly dream-enacting behavior), fatigue, and probably EDS are more frequently reported than in the general population even a decade prior to onset of motor Parkinson's disease signs (phase I). Gradually, as neuronal degeneration progresses, SWD increase in frequency and their spectrum expands. Dopaminergic medication often provides a relief on motor Parkinson's disease signs but has only a minor (or even a negative) impact on sleep-wake disturbances. EDS, excessive daytime sleepiness; PLMS, periodic limb movements in sleep; RBD, REM sleep behavior disorder; RLS, restless legs syndrome. and processing speed [19] and, as an important determinant of spindle production, with cognitive abilities [20, 21] , these findings contradict previous reports that patients with Parkinson's disease without REM sleep behavior disorder (RBD) showed a significantly lower sleep spindle density in non-REM sleep when compared to matched controls [22] . The inclusion of treated patients with Parkinson's disease in the Danish study may be a reasonable explanation for this discrepancy. However, the impact of dopaminergic medication on sleep architecture was not confirmed in a recent polysomnographic study. In 15 newly diagnosed patients with Parkinson's disease, after initiation of dopaminergic treatment, subjective sleepiness (assessed by Epworth sleepiness scale, ESS) improved but no significant changes in sleep macroarchitecture and other objective sleep parameters were found [23] .
DISRUPTION OF CIRCADIAN RHYTHM
Several normal circadian patterns are desynchronized in Parkinson's disease including diurnal fluctuation of sleep-wake cycles, cardiovascular (blood pressure, heart rate), and sensory functions [24 & ]. Recent studies focusing on circadian rhythmicity in early Parkinson's disease are limited. Breen et al. [7] showed that circadian alterations are linked to differences in peripheral clock gene expression and to fluctuations on circulating hormones also in early Parkinson's disease. Although there was no evidence of a melatonin phase shift in patients with Parkinson's disease compared to controls, alterations in melatonin secretion were significantly correlated with objective sleep parameters including sleep latency and reduced slow-wave sleep [7] . Interestingly, Lauretti et al. showed that circadian rhythm disruption may contribute to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity, suggesting that circadian disturbances might be a driving force for neurodegenerative processes [25] . However, symptomatic treatment with exogenous melatonin in patients with idiopathic RBD did not affect neurodegenerative outcome [26 && ]. Therefore, the hypothesis of circadian rhythm disorder as an environmental or endogenous risk factor for developing Parkinson's disease needs further investigation.
RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER
In patients with Parkinson's disease, RBD is prevalent in up to 50% (varying between 15 and 60%) [27, 28] , worsens with disease progression [29, 30] , and has a negative impact on quality of life [31] .
Rapid eye movement sleep behavior disorder is part of prodromal Parkinson's disease
In the last decade, many studies provided evidence that RBD precedes Parkinson's disease motor signs by several years, suggesting that RBD should no longer be considered a complication but a part of the prodromal phase of the disease [13, 32] [36, 37] . Interestingly, in the study from Beavan et al. [36] , GBA mutation carriers showed a significant deterioration in RBDQ over the 2 years of follow up, suggesting a progression of RBD symptoms already before any motor signs appear [36] . Finally, RBD prevalence significantly increased from the de-novo Parkinson's disease state to 2-year follow-up, suggesting that RBD may also represent a marker of Parkinson's disease progression [38
Conversion to synucleinopathy
A large proportion of patients with idiopathic RBD (iRBD) are susceptible to develop a synucleinopathy [2, 40, 41] . Patients with iRBD frequently reported NMS commonly found in advanced Parkinson's disease such as dribbling saliva, cognitive deficits, and hyposmia [42] . Moreover, the presence of RBD in the prodromal Parkinson's disease phase was associated with more cognitive deficits and with greater annual rate of cognitive decline, suggesting that RBD may be a risk factor for the development of dementia in Parkinson's disease [33 & ]. Recent efforts aimed at identifying factors that coexist with iRBD and can predict this phenoconversion. Among 89 patients with iRBD, about half developed a synucleinopathy over 10 years. Advanced age, loss of olfaction, abnormal color vision, motor function, and nonuse of antidepressants were associated with this conversion. Combining several of these markers, subpopulations can be identified with up to 65% conversion rates risk in 3 years [26 && ]. Interestingly, the presence of RBD symptoms in combination with hyposmia and cognitive decline in women could effectively differentiate de-novo Parkinson's disease cases from healthy controls [43] ], early biochemical changes, such as the downregulation of serum for specific miRNAs (miR-19b) [45] and specific genetic polymorphisms [46] have been also suggested as promising markers to predict phenoconversion of iRBD into a synucleinopathy.
PERIODIC LIMB MOVEMENTS IN SLEEP-RESTLESS LEGS SYNDROME
In patients with Parkinson's disease, periodic limb movements in sleep (PLMS) are present in 30-80% [47, 48] . Only one study assessed PLMS in early Parkinson's disease and reported no differences in the PLM-Index between untreated patients with Parkinson's disease and healthy controls [14] . The prevalence of restless legs syndrome (RLS), systematically reviewed in 18 Parkinson's disease cohorts by Rijsman et al. [49] varies between 0 and 50%, although rates close to zero were reported solely in the Asian population. For RLS, most of the studies showed no increased frequency before the onset of Parkinson's disease motor signs [50, 51] , despite other findings in some earlier reports [52] .
Recent studies support the concept of a relatively modest role of RLS as prodromal feature in Parkinson's disease. The frequency of RLS, assessed by specific questionnaires, did not differ among patients with Parkinson's disease, individuals at high risk for Parkinson's disease, and controls [53] . RLS assessed with the RLS Diagnostic Index was present at baseline in only 4.6% of newly diagnosed drug-naïve patients with Parkinson's disease and increased to 6.5% after 2 years and 16.3% after 4 years, suggesting that, in most patients, RLS is a complication rather than a prodromal feature of Parkinson's disease [54 ] . In line with these findings, the presence of RLS was not associated with risk for Parkinson's disease [52] . Notably, the presence of RLS in the premotor Parkinson's disease phase was related with delayed Parkinson's disease onset, reduced dyskinesia occurrence, and possibly slower progression of Parkinson's disease in comparison to matched patients with Parkinson's disease without RLS [55] . Genetic data strengthen further the notion that RLS and Parkinson's disease are likely to be distinct entities. Gan-Or et al. [56] analyzed the genetic profile of patients with Parkinson's disease and healthy controls regarding known and well-validated genetic RLS risk markers, and found no association with increased Parkinson's disease risk [56] .
SLEEP DISORDERED BREATHING
The prevalence of sleep disordered breathing (SDB) in Parkinson's disease varies between 20 and 66% [57, 58] , claiming higher rates than in the general population (9-17% among 50-to 70-year-old individuals [59] ) and an association with disease progression [60, 61] . However, other studies reported a similar or even reduced prevalence of SDB in Parkinson's disease compared to healthy controls [62, 63] . This discrepancy might reflect the small sample sizes, differences in methodology of the assessments and bias in patients selection and therefore the data should be interpreted with caution.
Although there are polysomnographic studies reporting the Apnea-Hypopnea-Index (AHI), to our best knowledge, studies assessing the prevalence of obstructive sleep apnea (OSA) in premotor or drug-naïve early motor Parkinson's disease are lacking. Recently, two population-based studies from Taiwan assessed the risk for developing Parkinson's disease in patients with OSA [64, 65] . The incidence of Parkinson's disease in the OSA cohort was approximately two times higher than that in individuals without OSA with women aged 50-69 and individuals with insomnia being at high risk [64] . These findings were confirmed by Sheu et al. [65] .
EXCESSIVE DAYTIME SLEEPINESS
Excessive daytime sleepiness (EDS) affects 15-50% of patients with Parkinson's disease [66] . With disease progression, EDS becomes very frequent and prominent [67] , and the addition of dopaminergic medication appears to worsen its severity [66] . In early studies, subjective sleepiness and short sleep latencies in the multiple sleep latency test indicative of objective EDS were present in some drug-naïve patients with Parkinson's disease but not more often than in controls [68] [69] [70] . However, men with EDS had a three-fold higher risk of developing Parkinson's disease than controls without EDS [71] .
Recently, studies based solely on subjective tools (e.g. ESS) to assess EDS in the early Parkinson [73] . Finally, Pont-Sunyer et al. [74] reported EDS to start after the onset of parkinsonism.
Demonstration that EDS might be a risk factor for neurodegeneration came recently from Arnulf et al. [75 & ] The authors assessed EDS with the ESS and concluded that EDS is frequent in patients with iRBD and that an ESS >8 at the time of iRBD diagnosis predicts more rapid conversion to parkinsonism and dementia [75 & ].
FATIGUE
Fatigue is present in about 60% (range between 33 and 70%) [76, 77] of individuals with Parkinson's disease. As the disease progresses, fatigue becomes very prominent and disabling [78] and has a negative impact on quality of life [79] . The addition of dopaminergic medication seems to worsen its severity. However, most of the data suggest that fatigue is related to disease progression, even in the premotor phase [80] [81] [82] . Recent studies support this notion: fatigue was the most frequently reported NMS in drug-naïve and treated patients with Parkinson's disease and its prevalence (57%) did not differ between the two groups. Demonstration that fatigue is part of the prodromal Parkinson's disease phase came from two recent studies. Schrag et al. [11 ] , based on medical records of 8166 individuals with and 46 755 individuals without PD, reported that fatigue precedes for several years the onset of typical motor signs and its prevalence is higher among individuals who will develop Parkinson's disease than those who will not. In agreement, fatigue, assessed by NMS-Questionnaire, was four-fold more frequent in 109 drug-naïve patients with Parkinson's disease compared to controls and was perceived up to 10 years prior to the onset of motor signs. In the same study, fatigue in combination with other NMS increased the ability to discriminate Parkinson's disease from controls, identifying fatigue as a possible biomarker of Parkinson's disease [10 && ].
SLEEP-WAKE NEUROBIOLOGY IN PRODROMAL PARKINSON'S DISEASE
In recent years, new hypotheses involving dopaminergic and nondopaminergic mechanisms emerged concerning sleep-wake neurobiology in Parkinson's disease ( Table 1) .
The dopaminergic system is related to the regulation of sleep and wakefulness at several levels. First, dopamine is implicated in circadian mechanisms including the light input and adaptation in the retina [102, 103] and the regulation of specific hormones, such as cortisol, prolactin, and melatonin [104] . The interaction between dopamine and melatonin [105] , a major regulator of the circadian rhythm, seems to be closely linked to Parkinson's disease progression [106, 107] . Second, the loss of dopaminergic transmission in Parkinson's disease not only affects the nigro-striatal projection but also dopaminergic circuits between basal ganglia and brainstem structures (particularly the pedunculopontine and laterodorsal tegmental nucleus), where important neurons of the arousal pathway and for the modulation of sleep stages are located [1, 101, 108] . Finally, mesocortical dopamine neurons innervate limbic areas (thalamus and hypothalamus) [1, 101] , where important regulators of sleep-wake cycle are located: a) the master circadian clock in the suprachiasmatic nuclei of the hypothalamus, which mainly involves coordinated expression and activation of various clock genes [109] [110] [111] [112] [113] [114] and regulation of melatonin production [115] , and b) orexin/hypocretin-containing neurons, important excitatory neuromodulators of sleep homeostasis [116] , which interestingly seem to be progressively reduced over the course of Parkinson's disease [117] .
The degeneration of other, non dopaminergic sleep-wake networks in the brainstem is likely to play also a crucial role in SWD in Parkinson's disease. Lower brainstem nuclei including the cholinergic pedunculopontine nucleus (PPN), the noradrenergic locus coeruleus, and the serotonergic raphe nuclei are directly involved with the regulation of both wakefulness and sleep [108] . It has been suggested, in agreement with the proposed Lewy pathology staging scheme [118] , that SWD in the prodromal phase of Parkinson's disease are directly related to neurodegeneration in these brainstem nuclei [2, 3, 84, 119] . Recently, De Natale et al. [120] showed that abnormalities in brainstem reflexes (vestibular-evoked myogenic potential) were more severe in patients with advanced Parkinson's disease compared with patients in the early phase and were significantly correlated with high scores on RBD Screening Questionnaire, an indicator for RBD severity. Similarly, dysfunction in brainstem ventilatory control mechanisms may be the link for the involvement of Parkinson's disease in the pathogenesis of SDB [93, 94] . 
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